Department of Health, Behavior, and Society, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States.
Department of Health, Behavior, and Society, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States.
Int J Drug Policy. 2019 Jun;68:46-53. doi: 10.1016/j.drugpo.2019.03.003. Epub 2019 Apr 13.
North America is experiencing a rising trend of opioid overdose exacerbated primarily in recent years through adulteration of the heroin supply with fentanyl and its analogues. The east coast of the United States has been particularly hard hit by the epidemic. In three east coast states of Maryland, Massachusetts and Rhode Island, fentanyl has been detected in over half of all overdoses with available toxicology screens. To determine the acceptability of drug checking involving fentanyl test strips (FTS) or other technologies among those at high risk for overdose, we assessed correlates of intention to utilize such services and logistical preferences among people who use drugs (PWUD).
Through FORECAST (the Fentanyl Overdose REduction Checking Analysis STudy), street-based PWUD (N = 334) were recruited in Baltimore, Maryland, Boston, Massachusetts, and Providence, Rhode Island. Questionnaires 7were administered from June to October 2017 and ascertained drug use, overdose history, fentanyl knowledge, and drug checking intent and logistical preferences. Pearson's χ and logistic regression determined factors associated with drug checking intent.
Overall, 84% were concerned about fentanyl, 63% had ever overdosed, and 42% had ever witnessed a fatal overdose. Ninety percent felt drug checking would help them prevent an overdose, the majority of those interested would utilize drug checking at least daily (54%). Factors independently associated with intent to use drug checking included: older age (aOR: 1.5, 95% CI: 1.3-1.8); homelessness (aOR: 0.6, 95% CI: 0.5-0.7); being non-white (aOR: 2.0, 95% CI: 1.0-4.0); witnessing ≥1 fatal overdose (aOR: 1.6, 95% CI:1.1-2.3); and suspected recent fentanyl exposure (aOR: 1.8, 95% CI: 1.1-3.1).
The majority of PWUD endorsed drug checking for overdose prevention, with intent amplified by having witnessed a fatal overdose and recent fentanyl exposure. Drug checking should be part of a comprehensive approach to address the risks associated with the proliferation of fentanyl.
北美地区正经历阿片类药物过量的上升趋势,这种趋势在近年来因海洛因供应中掺入芬太尼及其类似物而加剧。美国东海岸受该疫情的影响尤为严重。在马里兰州、马萨诸塞州和罗得岛州这三个东海岸州,在所有可进行毒理学检测的药物过量中,有超过一半都检测到了芬太尼。为了确定在有药物过量高风险的人群中,使用芬太尼检测条(FTS)或其他技术进行药物检测的可接受性,我们评估了那些有使用药物人群(PWUD)的意图使用此类服务的相关性因素和后勤偏好。
通过 FORECAST(芬太尼过量减少检测分析研究),在马里兰州巴尔的摩、马萨诸塞州波士顿和罗得岛州普罗维登斯,对街头 PWUD(N=334)进行了招募。2017 年 6 月至 10 月期间,通过问卷调查来确定药物使用情况、药物过量史、芬太尼知识以及药物检测意图和后勤偏好。采用 Pearson's χ 和逻辑回归来确定与药物检测意图相关的因素。
总体而言,84%的人对芬太尼感到担忧,63%的人曾有过药物过量,42%的人曾目睹过致命的药物过量。90%的人认为药物检测有助于他们预防药物过量,大多数有兴趣的人至少每天(54%)会使用药物检测。与使用药物检测的意图独立相关的因素包括:年龄较大(aOR:1.5,95%CI:1.3-1.8);无家可归(aOR:0.6,95%CI:0.5-0.7);非白人(aOR:2.0,95%CI:1.0-4.0);目睹过≥1 例致命药物过量(aOR:1.6,95%CI:1.1-2.3);和疑似最近芬太尼暴露(aOR:1.8,95%CI:1.1-3.1)。
大多数 PWUD 支持药物检测来预防药物过量,而目睹致命药物过量和最近芬太尼暴露则会增强这种意图。药物检测应该是解决与芬太尼扩散相关风险的综合方法的一部分。